Summary
The Pre-clinical Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the pre-clinical stage partnering agreements entered into by the worlds leading biopharma companies
Pre-clinical stage payment terms
Pre-clinical stage partnering contract documents
Pre-clinical stage partnering agreement terms
Pre-clinical stage partnering agreement structure
Top pre-clinical deals by value
Most active pre-clinical stage dealmakers
plus much more
Description
The Pre-clinical Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides detailed understanding and analysis of how and why companies enter pre-clinical stage licensing/business development and other forms of partnering arrangement.
The focus of the report is on partnerships for pre-clinical stage compounds where partners have joined forces to exploit these early stage opportunities. This is an early stage of partnering undertaken by commercial entities with the objective of utilizing promising drug candidates.
The report provides access to average pre-clinical stage deal payment terms as announced between the parties. This data provides useful insight into the average and range of payments for upfront, milestone and royalty payments agreed for pre-clinical stage deals.
This report contains over 1500 links to online copies of actual pre-clinical stage contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
The initial chapters of this report provide an orientation of pre-clinical stage dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in pre-clinical stage partnering as well as a discussion on the merits and attributes of dealmaking at the pre-clinical stage of development.
Chapter 3 provides an overview of the structure of pre-clinical stage partnering deal contracts. The chapter includes numerous case studies to enable understanding of pre-clinical stage partnering deals.
Chapter 4 provides a review of the leading pre-clinical stage partnering deals since 2000. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of pre-clinical stage contract documents available in the public domain. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive listing of all pre-clinical stage agreement contracts since 2003 available in the public domain, respectively. Each chapter is organized by company A-Z, therapeutic area, and deal type. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in pre-clinical stage dealmaking since 2000.
In conclusion, this report provides everything a prospective dealmaker needs to know about pre-clinical stage partnering, enabling thorough learning, education and due diligence prior and during the pre-clinical stage dealmaking process.
Report scope
Pre-clinical Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the pre-clinical stage partnering trends and structure of deals entered into by leading biopharma companies worldwide.
Pre-clinical Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:
- Trends in pre-clinical stage partnering dealmaking in the biopharma industry since 2000
- Analysis of pre-clinical stage partnering deal structure
- Case studies of real-life pre-clinical stage partnering deals
- Access to over 1500 pre-clinical stage partnering contract documents
- The leading pre-clinical stage partnering deals by value since 2000
- Most active pre-clinical stage partnering dealmakers since 2000
- The leading pre-clinical stage partnering resources
In Pre-clinical Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, the available contracts are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Deal type
- Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Benefits
Pre-clinical Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:
- In-depth understanding of pre-clinical stage partnering deal trends since 2000
- Analysis of the structure of pre-clinical stage partnering agreements with numerous real life case studies
- Comprehensive access to over 1500 actual pre-clinical stage partnering contracts entered into by the world's biopharma companies
- Detailed access to actual pre-clinical stage partnering contracts enter into by the leading fifty bigpharma companies
- Insight into the terms included in a pre-clinical stage partnering agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in pre-clinical stage dealmaking
- 2.1. Introduction
- 2.2. Difference between lead and pre-clinical compounds
- 2.2.1. Trends in pre-clinical stage deals since 2000
- 2.2.2. Upfront payments in pre-clinical stage deals
- 2.2.3. Milestone payments in pre-clinical stage deals
- 2.2.4. Royalty payments in pre-clinical stage deals
- 2.3. Attributes of pre-clinical stage deals
- 2.4. Reasons for entering into pre-clinical stage partnering deals
- 2.4.1. Licensors reasons for entering pre-clinical stage deals
- 2.4.2. Licensees reasons for entering pre-clinical stage deals
- 2.5. The future of pre-clinical stage partnering deals
Chapter 3 - Overview of pre-clinical stage deal structure
- 3.1. Introduction
- 3.2. The anatomy of a pre-clinical stage deal
- 3.3. Example pre-clinical stage
- 3.3.1. Case study 1: Tracon - Cell Matrix - Cancervax - March 2007
- 3.3.1. Case study 2: Pfizer - InSite Vision - February 2007
Chapter 4 - Leading pre-clinical stage deals
- 4.1. Introduction
- 4.2. Top pre-clinical stage deals by value
- 4.3. Top pre-clinical stage deals signed by bigpharma
- 4.4. Most active pre-clinical stage dealmakers
- 4.5. Bigpharma pre-clinical stage deal activity
Chapter 5 - Bigpharma pre-clinical stage partnering agreements
- 5.1. Introduction
- 5.2. How to use pre-clinical stage partnering agreements
- 5.3. Company pre-clinical stage partnering agreement listings
- Abbott
- Actavis
- Alcon Labs
- Allergan
- Amgen
- Amgen
- Astellas
- AstraZeneca
- Baxter International
- Bayer
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cephalon
- Chugai
- CSL
- Daiichi Sankyo
- Dainippon Sumitomo
- Eisai
- Eli Lilly
- Forest Laboratories
- Genentech
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- Hospira
- Johnson & Johnson
- Lundbeck
- Menarini
- Merck & Co
- Merck - Serono
- Mitsubishi
- Mylan
- Novartis
- Novo Nordisk
- Nycomed Pharma
- Otsuka
- Pfizer
- Procter & Gamble
- Ratiopharm
- Roche
- Sanofi-Aventis
- Schering Plough
- Servier
- Shire
- Solvay
- Takeda
- Teva
- UCB
- Watson
Chapter 6 - Pre-clinical partnering agreement directory 2003-early 2010
- 6.1. Introduction
- 6.2. Company A-Z
- 6.3. By therapy area
- Accident/Hospital/Trauma
- Blood/Lymphatic System
- Cardiovascular
- Central nervous System
- Dermatology
- Gastrointestinal
- Genetic
- Genitourinary
- Autoimmune/Inflammatory
- Infection
- Metabolism
- Musculoskeletal
- Oncology
- Respiratory
- Sensory Organ / Oral Health
- Delivery
- 6.4. By deal type
- Collaborative R&D
- Co-development
- Co-marketing
- Co-promotion
- Development
- Distribution
- Joint venture
- Licensing
- M&A
- Manufacturing
- Marketing
- Promotion
- Research
- Supply
Appendices
- Appendix 1 - Pre-clinical stage partnering references
- Appendix 2 - Resources
- Appendix 3 - Deal type definitions
- Appendix 4 - Example pre-clinical stage partnering contract
- About CurrentPartnering
- Recent report titles from CurrentPartnering
- Order Form - Reports
- Table of figures
- Figure 1: Definition of lead and pre-clinical compound dealmaking
- Figure 2: Trends in pre-clinical stage deal announcements, 2000-2009
- Figure 3: Upfront payments for clinical stage deals 2000-2009
- Figure 4: Milestone payments for clinical stage deals 2000-2009
- Figure 5: Royalty payments for clinical stage deals 2000-2009
- Figure 7: Components of the pre-clinical deal structure
- Figure 8: Top pre-clinical stage deals by value since 2003
- Figure 9: Bigpharma - top 50 - pre-clinical stage deals since 2003
- Figure 10: Most active pre-clinical stage dealmakers 2003-early 2010
- Figure 11: Bigpharma - top 50 - pre-clinical stage deals since 2003
- Figure 12: Online partnering resources
- Figure 13: Deal type definitions
- Figure 14: Partnering agreement between and Merck KGaA and Idera Pharmaceuticals - December 2007
